ASCO GU 2019: TROPHY-u-01: A Phase II Open-Label Study of Sacituzumab Govitecan (IMMU-132) in Patients with Advanced Urothelial Cancer after Progression on Platinum-Based Chemotherapy and/or Anti-PD-1/PD-L1 Checkpoint Inhibitor Therapy
San Francisco, CA (UroToday.com) Patients with metastatic urothelial carcinoma (mUC) have poor prognosis. Single-agent chemotherapy is the standard initial treatment and is associated with low response rates (6-14%) and poor overall survival (OS) 7 months. Anti-PD-1/PD-L-1 immunotherapy is presently used as second line therapy and is now the standard of care. For patients who progress after platinum chemotherapy and immunotherapy with programmed death ligand 1 (PD-1)/(PD-L1) inhibitors have limited treatment options.
ASCO GU 2019: Randomized Phase III Trial of Adjuvant Sequential Chemotherapy Plus Radiotherapy versus Adjuvant Radiotherapy Alone for Locally Advanced Bladder Cancer After Radical Cystectomy
San Francisco, CA (UroToday.com) In this study, the authors assess the role of adjuvant sequential chemotherapy and radiotherapy versus adjuvant radiotherapy alone for patients with locally advanced non-metastatic urothelial carcinoma of the bladder (Bladder cancer, BCa) following radical cystectomy (RC).
ASCO GU 2019: Keynote 057: Phase II trial of Pembrolizumab for Patients with High-risk NMIBC Unresponsive to BCG: Updated Interim Results
San Francisco, CA (UroToday.com) Non-muscle invasive bladder cancer (NMIBC) affects nearly 300,000 patients/year worldwide. High-risk NMIBC is defined as any carcinoma in situ, T1 tumor, and/or high-grade Ta disease.
The definition of BCG-unresponsive high-risk NMIBC is as follows:
- BCG refractory
- Stage progression at 3 months after adequate BCG induction (high-grade T1 at 3 months after initial CIS or high-grade Ta)
- Persistent high-risk NMIBC at 6 months despite adequate BCG
- BCG relapsing – recurrence of high-risk NMIBC after the patient achieves a disease-free state within 12 months after adequate BCG therapy
ASCO GU 2019: Whole Genome and Transcriptome Analysis of Metastatic Adrenocortical Carcinoma
San Francisco, CA (UroToday.com) Although adrenal cortical carcinoma (ACC) is a rare malignancy, it is a rather aggressive one, with approximately 40% of patients presenting with metastatic disease. The standard of care treatment is currently a combination of etoposide/doxorubicin/cisplatin (EDP) and mitotane. Unfortunately, ACC has a poor response to cytotoxic treatment and most patients with metastatic disease show progression.
ASCO GU 2019: Efficacy and Safety Data of the ARAMIS Study, Darolutamide in Nonmetastatic Castration-Resistant Prostate Cancer Patients
San Francisco, CA (UroToday.com) The treatment landscape for non-metastatic castration-resistant prostate (nmCRPC) cancer is rapidly evolving. In 2018, Enzalutamide (July 2018) and Apalutamide (February 2018) became the first two drugs to obtain FDA approval for the treatment of nmCRPC. SPARTAN was a phase 3 double-blind, randomized study of apalutamide versus placebo in patients nmCRPC.
ASCO GU 2019: Biologic Basis for Sequencing Novel Treatments for Metastatic Prostate Cancer
San Francisco, CA (UroToday.com) Dr. Beltran presented a summary of the biologic basis for sequencing novel treatments for metastatic prostate cancer.
There is an increasing need for biomarkers in advanced prostate cancer management – as there is a plethora of treatment options without much guidance about selection or sequencing. Some of the areas that require work are:
ASCO GU 2019: Randomized Phase III Trial of 68Ga-PSMA-11 PET/CT Molecular Imaging for Prostate Cancer Salvage Radiotherapy Planning
San Francisco, CA (UroToday.com) Salvage radiotherapy (SRT) for prostate cancer biochemical recurrence after radical prostatectomy (RP) is commonly administered to patients with PSA < 1 ng/mL, a threshold at which standard-of-care imaging is not sensitive enough to detect disease recurrence. 68Ga-PSMA-11 PET/CT (PSMA) PET/CT molecular imaging is highly sensitive for detecting regional and distant metastatic recurrent prostate cancer at low PSA levels. This lead to the assumption that PSMA can help guide and improve SRT.